Encorafenib (Braftovi®) accepted for use within NHSScotland

This is recommended for use in combination with cetuximab, for treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, who have received prior systemic therapy.

Scottish Medicines Consortium